No profile data available.
Virax Biolabs Group Limited (VRAX) is a healthcare company in the healthcare device wholesale industry, based in Lanarkshire, United Kingdom, with about 26 full-time employees.
It reported revenue of $6,331 for fiscal year 2025, down 96.0% from fiscal year 2024, and net income of -$6.06 million. Its market capitalization was $2.52 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
Virax Biolabs Group reported $6,331 in revenue for fiscal year 2025, down 96.0% from $156,419 in fiscal year 2024.
$2.52 million as of October 9, 2026.
Listed companies of a similar size in the same industry (healthcare device wholesale) include Henry Schein, Inc. (HSIC), Acme United Corporation (ACU), Vaso Corporation (VASO), Fuse Medical, Inc. (FZMD).